Endosomal escape: A bottleneck for LNP-mediated therapeutics
- PMID: 38437552
- PMCID: PMC10945858
- DOI: 10.1073/pnas.2307800120
Endosomal escape: A bottleneck for LNP-mediated therapeutics
Abstract
Lipid nanoparticles (LNPs) have recently emerged as a powerful and versatile clinically approved platform for nucleic acid delivery, specifically for mRNA vaccines. A major bottleneck in the field is the release of mRNA-LNPs from the endosomal pathways into the cytosol of cells where they can execute their encoded functions. The data regarding the mechanism of these endosomal escape processes are limited and contradicting. Despite extensive research, there is no consensus regarding the compartment of escape, the cause of the inefficient escape and are currently lacking a robust method to detect the escape. Here, we review the currently known mechanisms of endosomal escape and the available methods to study this process. We critically discuss the limitations and challenges of these methods and the possibilities to overcome these challenges. We propose that the development of currently lacking robust, quantitative high-throughput techniques to study endosomal escape is timely and essential. A better understanding of this process will enable better RNA-LNP designs with improved efficiency to unlock new therapeutic modalities.
Keywords: LNPs; RNA vaccines and therapeutics; endo-lysosomes; endosomal escape; mRNA.
Conflict of interest statement
Competing interests statement:D.P. receives licensing fees (to patents on which he was an inventor) from, invested in, consults (or on scientific advisory boards or boards of directors) for, lectured (and received a fee), or conducts sponsored research at TAU for the following entities: ART Biosciences, BioNtech SE, Eleven Therapeutics, Kernal Biologics, Merck, Newphase Ltd., NeoVac Ltd., RiboX Therapeutics, Roche, SirTLabs Corporation, and Teva Pharmaceuticals Inc. All other authors declare no competing financial interests.
Figures
References
-
- Lorenz C., et al. , Protein expression from exogenous mRNA: Uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway. RNA Biol. 8, 627–636 (2011). - PubMed
-
- Guan S., Rosenecker J., Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems. Gene Ther. 24, 133–143 (2017). - PubMed
-
- Couvreur P., Tulkenst P., Roland M., Trouet A., Speiser P., Nanocapsules: A new type of lysosomotropic carrier. FEBS Lett. 84, 323–326 (1977). - PubMed
-
- Sahin U., Karikó K., Türeci Ö., mRNA-based therapeutics–developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759–780 (2014). - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
